Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.45 |
| ▸ | ACACA | Q13085 | 5/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 6/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5964097 | 0.84 | TSHR (0.45) | PDE7AGSK3BPOLBPTGS2 | |
| SCHEMBL5963594 | 0.82 | PDE7A (0.46) | PDE7AGSK3BPTGS2AKR1B1 | |
| SCHEMBL5963575 | 0.78 | PDE7A (0.39) | ACACBACACAPDE7AGSK3BFPR2 | |
| SCHEMBL811962 | 0.78 | ACACB (0.55) | ACACBACACAPDE7A | |
| SCHEMBL6114105 | 0.77 | ACACB (0.75) | ACACBACACAPDE7AGSK3B | |
| SCHEMBL2356684 | 0.77 | ACACB (0.75) | ACACBACACAPDE7AGSK3B | |
| SCHEMBL2355636 | 0.77 | ACACB (0.75) | ACACBACACAPDE7AGSK3B | |
| SCHEMBL5963658 | 0.76 | AKR1B1 (0.40) | ACACBACACAPDE7AGSK3BFPR2 | |
| SCHEMBL2353419 | 0.75 | ACACB (0.77) | ACACBACACAPDE7AGSK3BMGAT2 | |
| SCHEMBL14690502 | 0.74 | NR1H2 (0.45) | ACACBACACARECQLFPR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125840-B2 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1326851-B1 | SUBSTITUTED DIPEPTIDES AS GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | GHSR, GHRHR, SSTR4 | ACACB 2760/4885ACACA 2933/4885PDE7A 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.